Start here when you need the Dubai market view first: live price tiers, batch proof, pen formats, delivery cutoff times, and the route into COA verification or checkout.
Each block below answers one common retatrutide question in a single pass. Trial figures cite published study data; supply notes apply to in-vitro laboratory research only.
Direct answer: Retatrutide (LY-3437943) is Eli Lilly's investigational once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. It remains in Phase 3 development (TRIUMPH programme) and is not approved by the FDA, EMA, or UAE MoHAP. Mechanism depth lives on the retatrutide profile.
Remy Peptides supplies research-grade formats for in-vitro laboratory use only under MoHAP Circular 17/2022.
Direct answer: In published Phase 2 and Phase 3 trials, the most common adverse events involved the gastrointestinal system—nausea, vomiting, and reduced appetite—especially during dose escalation, with changes in bowel habits and digestion also reported. These effects were generally most pronounced early in dose escalation and eased over the trial period. TRIUMPH-1 reported AE-driven discontinuation of 4.1–11.3% across dose arms vs 4.9% on placebo. Injection site reactions were generally mild and transient, and no serious organ-level safety signals have been identified in trials.
These are trial observations, not product claims. Full safety context: approval & trial tracker.
Direct answer: In published comparisons, retatrutide's triple-agonist design has reported higher mean weight change than semaglutide (~24% vs ~15% at comparable durations in Phase 2). TRIUMPH-1 reported 28.3% mean weight loss at 80 weeks on 12 mg. Retatrutide remains investigational.
Side-by-side context: retatrutide vs tirzepatide vs CagriSema.
Direct answer: Live research-use retatrutide in Dubai spans AED 350 to AED 2,000 across six formats; the 10mg vial is AED 350, the 40mg vial is AED 1,000 single or 2-pack and AED 900/vial at 5+ pack, and the flagship pens run AED 1,200 (20mg pen single) to AED 1,600 (30mg pen), with 5+ tiers from AED 1,300/pen (30mg) and AED 1,000/pen (20mg). Each released batch publishes Janoshik HPLC proof—flagship pen RETP002 at 99.262%. Free tracked UAE cold-chain delivery.
Live batch-linked tiers: Retatrutide UAE pricing matrix.
Direct answer: Remy Peptides ships all six listed retatrutide formats from Dubai (Al Barsha)—30mg, 20mg, 10mg, and 40mg pens plus 10mg and 40mg vials—with same-day cold-chain in Dubai (order by 4 PM) and next-day UAE-wide delivery. All six retatrutide formats remain listed as active in-stock research product pages. Flagship 30mg pen batch RETP002 tests at 99.262% HPLC; WhatsApp order tracking uses the verified contact ending 4686. For in-vitro laboratory research only—not a MoHAP-approved pharmacy medicine.
Supplier checklist: buy retatrutide Dubai guide · commercial formats: Retatrutide UAE.
Direct answer: Remy Peptides lists six Retatrutide formats in the UAE: 30mg pen (batch RETP002, 99.262% HPLC), 20mg pen (RET-20-C-2604-001, 99.841%), 10mg pen (COA pending), 40mg pen (RET-20-V-2604-001, 99.741%), 10mg vial (RET-20-V-2604-001, 99.741%), and 40mg vial (same batch line, 99.741%). All six listed retatrutide formats are currently in stock, including the 10mg pen, 40mg pen, and 40mg vial. Public Janoshik COAs are at the COA library, with per-batch reports for RETP002, RET-20-C-2604-001, and RET-20-V-2604-001. For Research Use Only.
Compare seal level, reconstitution, and AED/mg on Retatrutide UAE formats.
Direct answer: Orders confirmed dispatch next-day to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, and Umm Al Quwain via cold-chain packaging from Dubai. Dubai orders confirmed before 4 PM qualify for same-day hand-off (typical 2–4 hours).
Emirate delivery windows: Abu Dhabi · Sharjah · Retatrutide UAE hub.
Direct answer: Retatrutide is investigational—not a MoHAP-approved medicine. Research-use supply for in-vitro laboratory work is distinct from pharmacy sales and falls under MoHAP Circular 17/2022 framing. It must not be marketed or used for human or veterinary treatment.
Legal context: peptides legal in Dubai · approval status: is retatrutide approved?
Retatrutide is not MoHAP-approved as a medicine in the UAE and is not stocked by pharmacies — it remains an investigational triple-agonist compound. Research-grade retatrutide is available from UAE-based suppliers under the in-vitro framing of MoHAP Circular 17/2022, with batch purity verifiable through Janoshik Analytical COAs. Remy Peptides operates from Dubai (Al Barsha 1), supplies retatrutide strictly for in-vitro laboratory research, and ships UAE-wide with same-day Dubai tracked cold-chain delivery.
As of June 14, 2026, retatrutide in Dubai means research-use availability, not pharmacy access. This page covers the UAE details that matter most for due diligence: pen formats, price tiers, batch proof, delivery timing, and supplier-verification steps. For the regulatory answer, use the retatrutide approval status page. If you need a supplier checklist first, use the educational buying guide. For the consolidated commercial overview across the Emirates, see where to buy retatrutide in Dubai and the UAE.
| Feature | Retatrutide 30mg Pen | Retatrutide 20mg Pen |
|---|---|---|
| Format | Prefilled Pen | Prefilled Pen |
| Total Content | 30mg | 20mg |
| Clicks | 300 (0.1mg/click) | 300 (15 clicks/mg) |
| Purity | 99.262% HPLC | 99.841% HPLC |
| Lab Verification | Janoshik Analytical | Janoshik Analytical |
| Batch | RETP002 | RET-20-C-2604-001 |
| Price (1 pen) | AED 1,600 | AED 1,200 |
| Price (5+ pack) | AED 1,300/pen | AED 1,000/pen |
| Dubai Delivery | Same day | Same day |
| UAE Delivery | Next day | Next day |
Retatrutide (LY-3437943) is a triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor)—which is why this investigational peptide is often compared with single-receptor drugs in metabolic research. This triple mechanism of action has earned it the informal label “GLP-3” in online research communities, though no actual hormone by that name exists. Our triple-agonist pathway analysis explains how these three receptors interact at the molecular level.
In a pivotal Phase 2 trial published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2301972), Retatrutide demonstrated a 24.2% mean body weight reduction at the highest dose over 48 weeks—surpassing the efficacy observed with single-agonist (semaglutide, ~15%) and dual-agonist (tirzepatide, ~22.5%) compounds in comparable timeframes.
Eli Lilly’s Phase 3 program continues to read out — TRANSCEND-T2D1 (type 2 diabetes) returned positive top-line results on April 30, 2026 (A1c down 1.7–2.0 percentage points vs placebo; mean weight loss 11.1–16.6 kg), with detailed data due at the June ADA Scientific Sessions. The 80-week TRIUMPH-1 obesity trial reported positive topline results on May 21, 2026 — 28.3% mean weight loss at 80 weeks (up to 30.3% at 104 weeks in a BMI ≥35 extension), with all doses meeting primary and key secondary endpoints. As of May 21, 2026, Lilly has not announced an NDA filing date, and retatrutide remains investigational without FDA or UAE approval, with approval for therapeutic or commercial use still pending in global markets. This page is therefore limited to research-use sourcing context in Dubai; the full regulatory timeline lives on our retatrutide approval status page. For a UAE-specific check of current study listings, see our retatrutide clinical trials UAE review.
Published retatrutide trials have reported some of the largest body-weight changes seen in the investigational obesity-drug pipeline. In the Phase 2 study, participants assigned to the highest dose achieved a mean 24.2% body weight reduction over 48 weeks. These figures are clinical-trial observations only, not product claims or guidance for use.
The Phase 2 dose-finding study enrolled adults with obesity or overweight, with a BMI of 30 or above. Retatrutide produced dose-dependent weight-loss signals across treatment arms, with larger mean changes observed at higher doses. The 12 mg weekly arm reported body-weight reductions above 20% of baseline in the published dataset, exceeding semaglutide and tirzepatide figures from comparable GLP-1 trial contexts. For context on approved GLP-1 study data, see our Ozempic and Mounjaro before and after weight loss data.
Phase 3 TRIUMPH trials (ClinicalTrials.gov) are evaluating retatrutide in larger, more diverse study populations across multiple geographies. Researchers are watching whether the dataset confirms sustained body-weight change over longer durations and whether secondary endpoints include cardiovascular-risk markers, liver-fat reduction, and metabolic-syndrome outcomes. Dubai-based research institutions studying retatrutide mechanisms can access verified research-grade material through Remy Peptides.
Retatrutide’s triple-agonist mechanism targets appetite regulation, metabolic regulation, and overall metabolic control through multiple combined pathways. The GLP-1 component reduces appetite and hunger signals via hypothalamic satiety centres, while activation of glucagon receptors can contribute to increased energy expenditure, fat oxidation, and access to stored energy. The GIP component further supports glycemic regulation and control and influences adipose tissue insulin response. This triple-agonist approach represents an evolution in metabolic control compared to single and dual agonists.
GLP-1 receptor activation slows gastric emptying and enhances appetite suppression, reducing overall caloric intake. GIP receptor engagement further modulates appetite through central nervous system signalling. Together, these combined targets produce sustained hunger reduction and improved appetite control—contributing to the significant weight loss observed in clinical trials.
The glucagon receptor component specifically activates hepatic fat metabolism, metabolic rate, and metabolic processes associated with energy expenditure. Body-composition research also tracks changes in visceral fat and lipid profile. This pathway is one reason retatrutide differs from single- and dual-agonist comparators in trial design, and it remains a key focus for lipid-oxidation and body-composition research.
Beyond weight loss, retatrutide research has revealed significant improvements in blood sugar control and metabolic health markers. GLP-1 and GIP receptor activation enhances insulin secretion in a glucose-dependent manner, improving blood sugar regulation without increasing hypoglycaemia risk.
Patients with type 2 diabetes in the Phase 2 study showed improved insulin sensitivity and reduced HbA1c levels alongside weight loss. This dual benefit is important for researchers investigating metabolic syndrome, where obesity and diabetes co-occur. Retatrutide’s ability to address both blood sugar dysregulation and excess body weight through a single combination therapy molecule makes it a focus of metabolic-health research into weight management and sustainable weight loss.
Dubai’s extreme climate—with ambient temperatures regularly exceeding 45°C during summer months—makes cold-chain integrity critical for peptide research materials. Prefilled Pen formats offer distinct advantages over traditional lyophilised powder vials in this environment.
For research facilities in Dubai and across the UAE, the prefilled pen format reduces handling variables and supports consistent experimental protocols—critical factors when working with high-value research compounds. Our retatrutide dosage and titration guide covers the click-based dosing protocols used in published trials.
Remy Peptides offers tiered pricing for research institutions and laboratories conducting in-vitro studies with Retatrutide. Volume tiers reduce the per-pen cost for larger research programs, making multi-week protocols more accessible. All prices are in AED (United Arab Emirates Dirham) and include free tracked UAE delivery.
All orders include a Janoshik-verified Certificate of Analysis, temperature-controlled tracked cold-chain delivery, and WhatsApp support for order tracking and delivery coordination. Payment is accepted via card (secure payment link), cash on delivery, or USDT (TRC-20).
For bulk research orders or institutional procurement beyond the standard tiers, enquiries can be submitted via Telegram at @RemyPeptides. Bulk pricing is available for multi-month research protocols and laboratory supply agreements.
For laboratories running multi-week research protocols, the total cost per milligram is often more relevant than the per-pen price. Volume-tier pricing at Remy Peptides is designed to reduce the per-milligram cost for sustained research programs in the UAE.
Using the current 30mg pen tiers, the effective cost per milligram is:
For context, most research-grade retatrutide pens in the UAE market are priced between AED 1,400–1,800 per 30mg unit with limited volume incentives. The volume-tier structure at Remy Peptides is designed to support sustained research protocols—particularly the standard 24-week and 48-week titration schedules modelled on the TRIUMPH clinical trial design—without requiring repeated single-unit procurement at premium rates.
This pricing applies to all UAE orders, with same-day Dubai dispatch and the same temperature-controlled logistics regardless of order size.
The key differentiator for Retatrutide is its triple-receptor mechanism. Approved GLP-1 therapies and next-generation compounds vary in the number of metabolic receptors they engage, which directly correlates with observed efficacy in clinical trials.
For a local overview of approved options, compare Ozempic in Dubai, Mounjaro in Dubai, and our weight loss injections in Dubai guide.
The addition of the glucagon receptor agonism is hypothesised to increase energy expenditure and hepatic lipid oxidation, potentially contributing to the incremental efficacy observed over dual-agonist compounds. Phase 3 data from the TRIUMPH program will provide definitive comparative results. Browse our best retatrutide supplier Dubai guide for a COA-focused supplier comparison.
For a detailed breakdown including efficacy comparisons, dosing schedules, and mechanism analysis, see our full Retatrutide vs Tirzepatide vs CagriSema comparison.
Remy Peptides provides temperature-controlled delivery for all research peptide orders across the United Arab Emirates. Delivery timelines vary by emirate, with all shipments dispatched from our Dubai facility using insulated cold-chain packaging. For a complete overview of available compounds beyond retatrutide, see our research peptides in Dubai page or the wider Research peptides UAE catalogue.
All shipments use insulated, temperature-controlled packaging to maintain cold-chain integrity from dispatch to laboratory receipt. This is especially critical during summer months when ambient temperatures in the UAE regularly exceed 45°C.
For order tracking, delivery coordination, or research enquiries, contact us via WhatsApp. Support is available 7 days a week, 10 AM to 10 PM UAE time. We also accept enquiries in Arabic via WhatsApp.
Long-term interpretation of GLP-1-class trial data increasingly looks beyond drug exposure alone. Retatrutide and related metabolic-agent research often tracks lifestyle variables, resistance training, nutritional intake, lean-mass preservation, and metabolic monitoring as confounders or secondary context. Those variables help researchers interpret body-composition and durability signals without turning trial findings into consumer guidance.
The development of next-generation metabolic agents such as retatrutide has significant public-health research implications, particularly in the UAE where obesity prevalence exceeds 30%. Researchers are studying factors that influence trial response, including genetics, baseline metabolic health, and lifestyle variables. Outcomes vary across study cohorts, which is why this page treats efficacy data as research context rather than a prediction for individual use.
Retatrutide is supplied for in-vitro laboratory research only under UAE MoHAP Circular 17/2022. It is not approved for human or veterinary use and should not be marketed, prescribed, dispensed, or used as a treatment product.
Remy Peptides supplies retatrutide exclusively for in-vitro research purposes. All materials carry “For Research Use Only” labelling, and no therapeutic claims are made. It also has no regulatory approval for therapeutic use in the UAE. This is distinct from prescription GLP-1 medications like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), which are regulated pharmaceuticals available only through licensed pharmacies with a prescription in the UAE.
For a broader overview of peptide legality across jurisdictions, see our peptide legality guide by country. For a Dubai-specific reading of the public-source compliance position, see our Dubai legality brief.
As of May 21, 2026, retatrutide is not available through any UAE pharmacy, clinic, or hospital. Access remains limited to research settings and active clinical-trial environments rather than retail medical channels. Eli Lilly’s Phase 3 trials are ongoing globally — the pivotal TRIUMPH-1 obesity trial reported positive topline results on May 21, 2026 (28.3% at 80 weeks, up to 30.3% at 104 weeks), and TRANSCEND-T2D1 read out positive earlier in 2026 — but Lilly has not announced an NDA filing date. Even after any future approval, UAE availability through clinical channels would require separate regulatory review by the UAE Ministry of Health and Prevention (MoHAP).
For researchers who require retatrutide for in-vitro laboratory studies, Remy Peptides is currently the only UAE-based supplier offering Janoshik-verified, HPLC-tested material with same-day Dubai delivery and full certificate of analysis documentation. The prefilled pen format eliminates the need for reconstitution, reducing contamination risk and handling time in laboratory settings.
Retatrutide availability in Dubai for research purposes is supported through Remy Peptides. As a pre-approval investigational drug, retatrutide is not yet available through pharmacies or clinical channels in the UAE. For a global overview of sourcing options and quality verification criteria, see our supplier checklist. Remy Peptides provides retatrutide in Dubai exclusively for in-vitro laboratory research, with all materials clearly labelled “For Research Use Only.”
Dubai-based researchers studying retatrutide can focus on mechanism validation, receptor binding assays, or metabolic pathway analysis using our HPLC-verified research-grade peptides. For a broader look at what is driving research demand in the region, see our peptide trends in the UAE for 2026. For a complete guide to peptide therapy options in Dubai—clinics, costs, and research-grade access—see our peptide therapy Dubai guide. For questions about retatrutide research use, availability, or bulk procurement in Dubai, contact our research support team via WhatsApp.
To buy Retatrutide in Dubai, the Remy Peptides store is the main ordering destination, and this page is the Dubai market explainer that routes you there. Remy Peptides supplies all six listed retatrutide formats with same-day Dubai delivery: 30mg, 20mg, 10mg, and 40mg prefilled pens plus 10mg and 40mg vials. 30mg pen pricing starts at AED 1,300 per pen at the 5+ tier, with AED 1,600 per pen for single-pen orders; the 10mg vial is AED 350/vial, and the 40mg vial is AED 900–1,000/vial depending on quantity.
The fastest route is: review the COA library for batch RETP002, confirm your pen count with the calculator, then order the Retatrutide 30mg Pen, the Retatrutide 20mg Pen, or compare all UAE retatrutide formats. For a step-by-step guide covering supplier evaluation, purity verification, and format selection, read our complete guide to buying retatrutide in Dubai.
Retatrutide (LY-3437943) activates the GLP-1 receptor — the same pathway targeted by semaglutide (Ozempic/Wegovy). However, retatrutide also activates GIP and glucagon receptors simultaneously, making it a triple-agonist rather than a single-pathway drug. In Phase 2 trials, retatrutide produced 24.2% mean body weight reduction at 48 weeks, compared to 14.9% for semaglutide and 22.5% for tirzepatide. Retatrutide is currently in Phase 3 trials (TRIUMPH program) and is not yet approved for any therapeutic use — track its filing status alongside the wider pipeline in our obesity-drug approval trackers.
Yes. Semaglutide (Ozempic/Wegovy) is a modified GLP-1 peptide analogue — a 31-amino-acid peptide based on native human GLP-1(7-37) with an Aib substitution at position 8 and a C18 fatty diacid side chain enabling once-weekly dosing. The Retatrutide 30mg Pen is also peptide-based but activates three receptors (GLP-1, GIP, GCGR) compared to semaglutide’s single GLP-1 target, which is why Phase 2 data shows superior weight reduction (24.2% vs 14.9%).
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →